<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637139</url>
  </required_header>
  <id_info>
    <org_study_id>ABI H0731 108</org_study_id>
    <nct_id>NCT04637139</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Mass Balance Absorption and AME of VBR</brief_title>
  <official_title>An Open Label Phase 1 Study in Healthy Adult Male Subjects to Determine the Mass Balance Recovery, Absorption, Metabolism, and Excretion of [14C] Vebicorvir Following Single Oral Dose Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assembly Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assembly Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 Study will determine the mass balance recovery, absorption, metabolism, and&#xD;
      excretion of [14C] Vebicorvir in healthy male subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Actual">December 22, 2020</completion_date>
  <primary_completion_date type="Actual">December 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass Balance: Cumulative Amount of [14C] Radiolabel Excreted in Urine up to the Last Sampling Interval (Ae-urine, 14C)</measure>
    <time_frame>Before dosing and at prespecified time intervals up to 168 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass Balance: Cumulative Amount of [14C] Radiolabel Excreted in Feces up to the Last Sampling Interval (Ae-feces, 14C)</measure>
    <time_frame>Before dosing and at prespecified time intervals up to 168 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with One or More Adverse Events</measure>
    <time_frame>Up to 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Discontinued from the Study Due to an Adverse Event</measure>
    <time_frame>Up to 168 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VBR 300 mg solution containing 2 µCi [14C]VBR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vebicorvir (VBR)</intervention_name>
    <description>300mg Vebicovir containing 2 µCi [14C]VBR.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Consent&#xD;
&#xD;
          -  Male between 18 and 55 years of age (inclusive) at the time of Screening&#xD;
&#xD;
          -  Body mass index (BMI) between ≥18.0 kg/m2 and ≤32.0 kg/m2 at Screening; body weight&#xD;
             between ≥55.0 kg and ≤100.0 kg at Screening&#xD;
&#xD;
          -  Considered to be in good health by the Investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of any condition (e.g., chronic diarrhea) or prior surgery (e.g.,&#xD;
             gastric bypass)&#xD;
&#xD;
          -  Clinically significant abnormal medical history&#xD;
&#xD;
          -  History of cancer that has not been in full remission for &gt;5 years&#xD;
&#xD;
          -  Acute illness within 14 days prior to study drug administration&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pharmaron CPC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CHB</keyword>
  <keyword>HBV</keyword>
  <keyword>hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

